Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients

Abstract

RZV administration in patients with IMIDs was generally well-tolerated, though mild flares were not uncommon in the first 12 weeks after vaccination. These data may provide useful information for patient education when considering RZV administration.